Compare AU
Compare PGTX vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are PGTX and DRUG. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.
Community Stats
--- | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 63 |
Median incremental investment | - | $967.00 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,875.72 |
Average age group | N/A | 26 - 35 |
Key Summary
--- | DRUG | |
|---|---|---|
Strategy | N/A | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | N/A | 0.57 % |
Key Summary
--- | DRUG | |
|---|---|---|
Issuer | N/A | BetaShares |
Tracking index | N/A | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | Stock | ETF |
Management fee | N/A | 0.57 % |
Price | $-- | $8.12 |
Size | N/A | $191.120 million |
10Y return | N/A | N/A |
Annual dividend/ distribution yield (5Y) | - % | 1.90 % |
Market | ASX | ASX |
First listed date | N/A | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
--- | DRUG | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 63 |
Median incremental investment | - | $967.00 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $1,875.72 |
Average age group | N/A | 26 - 35 |
Pros and Cons
--- | DRUG | |
|---|---|---|
Pros |
| |
Cons |
|
--- | DRUG |
|---|---|
Exposure to 1 market and 1 sector only | Exposure to more markets and sectors |
Lower price growth | Higher price growth |
Lower dividend/distribution yield | Higher dividend/distribution yield |